Article · 13 Oct 2026
Review articlePublished 30 Sep 2021
Potential use of Ribosome Inactivating Proteins (RIPS) as Cancer Therapeutic and its Indigenous Sources
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ribosome-Inactivating Proteins (RIPs) are enzymes that have demonstrated remarkable cytotoxic activity linked to the ability of N-glycosidase activity in 28S ribosomal RNA to inactivate protein synthesis (rRNA). There are many sources of RIPs, but they are mainly found in plants, fungi, algae, and in some bacterial species. “The RIPs exactly bind with large ribosomal subunit and cleavage the specific base of adenine at 28S rRNA by N-glycosidase activity and stop protein translation”. Many factors suggest that the host could be protected from predators and viruses without losing its involvement in stress reactions or the preservation of nitrogen. Previous studies have reported the great potential of RIPs for use as cancer therapeutics. RIPs are specific in their function through targeting only cancer cells and less toxicity regarding normal cells. The main feature of RIPs used as cancer treatment is their short plasma half-life, antigenicity, and selective cytotoxicity. The pharmaceutical property of RIPs might be improved by coupling the RIPS with polyethylene glycol, which improves plasma time and decreases its antigenicity. We reviewed previous literature providing evidence about therapeutic approaches regarding RIPs due to their potential as a therapeutic application in different types of human diseases. RIPS functions as a target-specific carrier by its conjugation with toxins.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Annals of Medical and Health Sciences Research.
Article · 10 Jun 2026
Understanding High-Functioning Depression: A Narrative Review of Diagnostic Challenges, Nosological Frameworks, and Clinical Implications
Article · 14 Apr 2026
An Open-Label Clinical Study On Safety And Gastrointestinal Tolerance Of Maxvida™ High Protein In Hospitalized Adults Requiring Isocaloric Enteral Feeding
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAnnals of Medical and Health Sciences Research
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Quratulain Maqsood”
- BylineArticles whose byline prints “Aleena Sumrin”
- BylineArticles whose byline prints “Muhammada Mahnoor”
- BylineArticles whose byline prints “Muhammad Waseem”
- BylineArticles whose byline prints “Esha Ameen”
- BylineArticles whose byline prints “Natasha Tabassum”